Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Clinical neurodiagnostics

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels.

Ali Manouchehrinia; Fredrik Piehl; Jan Hillert; Jens Kuhle; Lars Alfredsson; Tomas Olsson; Ingrid Kockum

Originally published in Annals of clinical and translational neurology · 2020-01-01

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Blood Neurofilament light chain (NfL) has been suggested as a promising biomarker in several neurological conditions. Since blood NfL is the consequence of leaked NfL from the cerebrospinal fluid, differences in individuals' Body Mass Index (BMI) or blood volume (BV) might affect its correlation to other biomarkers and disease outcomes. Here, we investigated the correlation between plasma NfL, BMI, and BV in 662 controls and 2,586 multiple sclerosis cases. We found a significant negative correlation between plasma NfL, BMI/BV in both groups. Our results highlight the potential confounding effect of BMI/BV on associations between blood NfL and disease outcomes.

Materials and Methods

Blood samples and self‐reported weight and height measures from population‐based controls and multiple sclerosis (MS) cases were collected, concurrently as part of the Epidemiological Investigation of MS (EIMS)4 and Immunomodulation and MS Epidemiology (IMSE) projects5 in Sweden. Concentrations of plasma NfL (pNfL) were determined with antibodies from UmanDiagnostics and the high‐sensitive Single Molecule Array (SimoaTM) NF‐light® Advantage kit. Detailed information on the study participants and study procedure has been previously described.6, 7

Results

We included 662 population‐based controls and 2,586 MS cases. Median pNfL level was 7.52 pg/mL (interquartile range (IQR): 5.87–9.87) in controls and 11.68 pg/mL (IQR: 8.27–18.46) in cases. There was no significant differences in proportion of females (75.2% vs. 72.6%, P = 0.19), sampling age (40 vs. 40, P = 0.97) and BMI (23.79 vs. 24.10, P = 0.1) between cases and controls. However, BV was significantly lower in cases compared to controls (4.44 vs 4.51, P = 0.03).

Discussion

Plasma NfL concentrations have been shown to have a moderate correlation to different clinical and imaging outcomes in MS. The fact that we here see also a correlation with BMI and BV suggests that such correlations might change if corrections for BV or BMI (since both measures are driven by height and weight) are included. Also, from a generic point of view our findings underscore the potential importance of taking BV or BMI into account when analyzing neuronal biomarkers in blood.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?